Andrew Conroy

495 total citations
12 papers, 255 citations indexed

About

Andrew Conroy is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Andrew Conroy has authored 12 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 2 papers in Pharmacology. Recurrent topics in Andrew Conroy's work include CAR-T cell therapy research (5 papers), Cancer therapeutics and mechanisms (3 papers) and CRISPR and Genetic Engineering (2 papers). Andrew Conroy is often cited by papers focused on CAR-T cell therapy research (5 papers), Cancer therapeutics and mechanisms (3 papers) and CRISPR and Genetic Engineering (2 papers). Andrew Conroy collaborates with scholars based in United States, Italy and Germany. Andrew Conroy's co-authors include Rachael E. Hawtin, Judith A. Fox, David E. Stockett, Michelle R. Arkin, Duncan Walker, Ute Hoch, Jo Ann W. Byl, Nguyêñ Duy Tân, Neil Osheroff and Wenjin Yang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Andrew Conroy

11 papers receiving 251 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Conroy United States	5	165	124	60	46	31	12	255
Brandon Carter‐Cooper United States	13	222 1.3×	70 0.6×	36 0.6×	104 2.3×	29 0.9×	25	350
Kwong-Him To Canada	2	177 1.1×	170 1.4×	22 0.4×	17 0.4×	38 1.2×	2	261
Rebecca A. Bilardi Australia	8	219 1.3×	68 0.5×	16 0.3×	71 1.5×	12 0.4×	11	292
Lena M. Berger Germany	9	159 1.0×	70 0.6×	39 0.7×	17 0.4×	27 0.9×	19	234
Gordafaried Deyanat‐Yazdi United States	5	259 1.6×	95 0.8×	69 1.1×	36 0.8×	5 0.2×	8	331
Brian G. Hartl New Zealand	6	167 1.0×	58 0.5×	115 1.9×	48 1.0×	6 0.2×	6	295
Karen Fehn United States	6	126 0.8×	135 1.1×	22 0.4×	29 0.6×	24 0.8×	12	232
Viacheslav V. Senichkin Sweden	8	241 1.5×	93 0.8×	20 0.3×	24 0.5×	17 0.5×	13	302
Ziqin Yan China	10	210 1.3×	85 0.7×	88 1.5×	43 0.9×	20 0.6×	22	307
Lipeng Dai United States	7	227 1.4×	116 0.9×	41 0.7×	55 1.2×	39 1.3×	8	329

Countries citing papers authored by Andrew Conroy

Since Specialization

Citations

This map shows the geographic impact of Andrew Conroy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Conroy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Conroy more than expected).

Fields of papers citing papers by Andrew Conroy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Conroy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Conroy. The network helps show where Andrew Conroy may publish in the future.

Co-authorship network of co-authors of Andrew Conroy

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Conroy. A scholar is included among the top collaborators of Andrew Conroy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Conroy. Andrew Conroy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Rubinstein, Morton, et al.. (2025). Krüppel-like Factor 4-Deficient Cells Are Sensitive to Etoposide-Induced DNA Damage. Current Issues in Molecular Biology. 47(4). 217–217.

Sennino, Barbara, Jyoti Mathur, Andrew Conroy, et al.. (2022). Abstract 563: Circulating tumor-specific T cells preferentially recognize patient-specific mutational neoantigens and infrequently recognize shared cancer driver mutations. Cancer Research. 82(12_Supplement). 563–563. 2 indexed citations

Sennino, Barbara, Andrew Conroy, Bhamini Purandare, et al.. (2020). Abstract 895: Coexpression of MHC class I-restricted neoTCRs and ectopic CD8 receptors in precision genome engineered CD4 T cells significantly potentiates antigen-specific effector functions. Cancer Research. 80(16_Supplement). 895–895. 1 indexed citations

Sennino, Barbara, Andrew Conroy, Bhamini Purandare, et al.. (2019). Abstract 1433: NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’ phenotypes that rapidly proliferate and kill target cells upon recognition of cognate antigen. Cancer Research. 79(13_Supplement). 1433–1433. 2 indexed citations

Jacoby, Kyle, Robert Moot, William Lu, et al.. (2019). Abstract 4783: Highly efficient, non-viral precision genome engineering for the generation of personalized neoepitope-specific adoptive T cell therapies. Cancer Research. 79(13_Supplement). 4783–4783. 1 indexed citations

Rosen, David B., Ling Yan Leung, Andrew Conroy, et al.. (2014). Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP). Journal of Translational Medicine. 12(1). 184–184. 6 indexed citations

Alvarado, Ryan, Andrew Conroy, Santosh Putta, et al.. (2013). Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification. Journal for ImmunoTherapy of Cancer. 1(S1). 1 indexed citations

Hawtin, Rachael E., David E. Stockett, Jo Ann W. Byl, et al.. (2010). Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II. PLoS ONE. 5(4). e10186–e10186. 127 indexed citations

Conroy, Andrew, David E. Stockett, Duncan Walker, et al.. (2009). SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemotherapy and Pharmacology. 64(4). 723–732. 106 indexed citations

10.

Karp, Judith E., Linda Cripe, Gail J. Roboz, et al.. (2009). Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients. Journal of Clinical Oncology. 27(15_suppl). 7005–7005. 4 indexed citations

11.

Conroy, Andrew, Nguyen Tan, Oi Kwan Wong, Judith A. Fox, & Rachael E. Hawtin. (2009). Abstract C226: Clinical evidence of mechanism-based activity in voreloxin-treated AML patients. Molecular Cancer Therapeutics. 8(12_Supplement). C226–C226. 1 indexed citations

12.

Black, W D, Paul Thompson, Adam Funk, & Andrew Conroy. (2003). Learning to Classify Utterances in a Task-Oriented Dialogue. Conference of the European Chapter of the Association for Computational Linguistics. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact